Transgene SA (TRGNF)
USD 1.59
(0.0%)
USD 1.59
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -28.4 Million EUR | 2.2% |
| 2022 | -29.04 Million EUR | -26.88% |
| 2021 | -22.89 Million EUR | 6.05% |
| 2020 | -24.36 Million EUR | 1.49% |
| 2019 | -24.73 Million EUR | 4.9% |
| 2018 | -26 Million EUR | -306.3% |
| 2017 | -6.4 Million EUR | -2171.52% |
| 2016 | 309 Thousand EUR | 126.39% |
| 2015 | -1.17 Million EUR | 90.79% |
| 2014 | -12.71 Million EUR | -1.27% |
| 2013 | -12.55 Million EUR | -419.53% |
| 2012 | 3.92 Million EUR | 110.18% |
| 2011 | -38.6 Million EUR | -35.88% |
| 2010 | -28.4 Million EUR | -33.61% |
| 2009 | -21.26 Million EUR | -16.04% |
| 2008 | -18.32 Million EUR | -2249.1% |
| 2007 | -780 Thousand EUR | 95.81% |
| 2006 | -18.6 Million EUR | 0.0% |
| 2004 | 2.51 Million EUR | 0.52% |
| 2003 | 2.5 Million EUR | 13.37% |
| 2002 | 2.2 Million EUR | 75.08% |
| 2001 | 1.26 Million EUR | -73.33% |
| 2000 | 4.72 Million EUR | 9.23% |
| 1999 | 4.32 Million EUR | -57.32% |
| 1998 | 10.13 Million EUR | 90.05% |
| 1997 | 5.33 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -6.03 Million EUR | -10.88% |
| 2024 Q2 | -6.03 Million EUR | 0.0% |
| 2023 Q4 | -5.44 Million EUR | 0.0% |
| 2023 FY | -28.4 Million EUR | 2.2% |
| 2023 Q1 | -5.4 Million EUR | 20.18% |
| 2023 Q2 | -6.62 Million EUR | -22.68% |
| 2023 Q3 | -5.44 Million EUR | 17.92% |
| 2022 Q4 | -6.76 Million EUR | -23.78% |
| 2022 FY | -29.04 Million EUR | -26.88% |
| 2022 Q2 | -6.18 Million EUR | -13.7% |
| 2022 Q3 | -5.46 Million EUR | 11.64% |
| 2022 Q1 | -5.44 Million EUR | -3788.21% |
| 2021 Q1 | -5.17 Million EUR | 14.2% |
| 2021 Q3 | -2.64 Million EUR | 58.04% |
| 2021 FY | -22.89 Million EUR | 6.05% |
| 2021 Q2 | -6.3 Million EUR | -21.9% |
| 2021 Q4 | -140 Thousand EUR | 94.71% |
| 2020 Q3 | -4.58 Million EUR | 1.6% |
| 2020 Q1 | -4.3 Million EUR | -35.68% |
| 2020 Q2 | -4.66 Million EUR | -8.37% |
| 2020 Q4 | -6.03 Million EUR | -31.52% |
| 2020 FY | -24.36 Million EUR | 1.49% |
| 2019 Q2 | -5.87 Million EUR | -16.57% |
| 2019 Q1 | -5.03 Million EUR | -1.38% |
| 2019 Q3 | -4 Million EUR | 31.73% |
| 2019 Q4 | -3.16 Million EUR | 20.92% |
| 2019 FY | -24.73 Million EUR | 4.9% |
| 2018 FY | -26 Million EUR | -306.3% |
| 2018 Q1 | -5.16 Million EUR | -1505.29% |
| 2018 Q2 | -5.16 Million EUR | 0.0% |
| 2018 Q3 | -4.96 Million EUR | 3.74% |
| 2018 Q4 | -4.96 Million EUR | 0.0% |
| 2017 FY | -6.4 Million EUR | -2171.52% |
| 2017 Q4 | -321.5 Thousand EUR | 0.0% |
| 2017 Q2 | -200 Thousand EUR | 0.0% |
| 2017 Q1 | -200 Thousand EUR | -751.06% |
| 2017 Q3 | -321.5 Thousand EUR | -60.75% |
| 2016 Q2 | 587.5 Thousand EUR | 0.0% |
| 2016 FY | 309 Thousand EUR | 126.39% |
| 2016 Q4 | -23.5 Thousand EUR | 0.0% |
| 2016 Q3 | -23.5 Thousand EUR | -104.0% |
| 2016 Q1 | 587.5 Thousand EUR | 718.42% |
| 2015 FY | -1.17 Million EUR | 90.79% |
| 2015 Q4 | -95 Thousand EUR | 0.0% |
| 2015 Q2 | 577.5 Thousand EUR | 0.0% |
| 2015 Q3 | -95 Thousand EUR | -116.45% |
| 2015 Q1 | 577.5 Thousand EUR | 161.6% |
| 2014 Q4 | -937.5 Thousand EUR | 0.0% |
| 2014 Q3 | -937.5 Thousand EUR | 15.77% |
| 2014 Q1 | -1.11 Million EUR | -371.13% |
| 2014 FY | -12.71 Million EUR | -1.27% |
| 2014 Q2 | -1.11 Million EUR | 0.0% |
| 2013 Q2 | -742.99 Thousand EUR | 0.0% |
| 2013 Q4 | 410.5 Thousand EUR | 0.0% |
| 2013 Q3 | 410.5 Thousand EUR | 155.25% |
| 2013 FY | -12.55 Million EUR | -419.53% |
| 2013 Q1 | -742.99 Thousand EUR | 0.0% |
| 2012 FY | 3.92 Million EUR | 110.18% |
| 2011 FY | -38.6 Million EUR | -35.88% |
| 2010 FY | -28.4 Million EUR | -33.61% |
| 2009 FY | -21.26 Million EUR | -16.04% |
| 2008 FY | -18.32 Million EUR | -2249.1% |
| 2007 FY | -780 Thousand EUR | 95.81% |
| 2006 FY | -18.6 Million EUR | 0.0% |
| 2005 Q1 | 1.01 Million EUR | 42.1% |
| 2005 Q2 | 1.08 Million EUR | 7.35% |
| 2004 Q3 | 832.52 Thousand EUR | 91.47% |
| 2004 Q2 | 434.8 Thousand EUR | -33.46% |
| 2004 Q1 | 653.43 Thousand EUR | 4.45% |
| 2004 Q4 | 713.68 Thousand EUR | -14.27% |
| 2004 FY | 2.51 Million EUR | 0.52% |
| 2003 Q2 | 424.08 Thousand EUR | -52.63% |
| 2003 FY | 2.5 Million EUR | 13.37% |
| 2003 Q3 | 556.43 Thousand EUR | 31.21% |
| 2003 Q1 | 895.34 Thousand EUR | -43.86% |
| 2003 Q4 | 625.59 Thousand EUR | 12.43% |
| 2002 Q2 | 110.36 Thousand EUR | 33.73% |
| 2002 FY | 2.2 Million EUR | 75.08% |
| 2002 Q1 | 82.53 Thousand EUR | -76.33% |
| 2002 Q3 | 417.88 Thousand EUR | 278.63% |
| 2002 Q4 | 1.59 Million EUR | 281.64% |
| 2001 Q2 | 168.91 Thousand EUR | -71.99% |
| 2001 FY | 1.26 Million EUR | -73.33% |
| 2001 Q4 | 348.61 Thousand EUR | 153.98% |
| 2001 Q3 | 137.25 Thousand EUR | -18.74% |
| 2001 Q1 | 602.94 Thousand EUR | -63.47% |
| 2000 Q1 | 728.41 Thousand EUR | -14.38% |
| 2000 FY | 4.72 Million EUR | 9.23% |
| 2000 Q4 | 1.65 Million EUR | 162.92% |
| 2000 Q3 | 627.81 Thousand EUR | -63.24% |
| 2000 Q2 | 1.7 Million EUR | 134.44% |
| 1999 Q1 | 1.48 Million EUR | -57.2% |
| 1999 FY | 4.32 Million EUR | -57.32% |
| 1999 Q2 | 1.26 Million EUR | -14.94% |
| 1999 Q4 | 850.77 Thousand EUR | 13.26% |
| 1999 Q3 | 751.18 Thousand EUR | -40.41% |
| 1998 Q4 | 3.46 Million EUR | 710.45% |
| 1998 Q1 | 7.94 Million EUR | 0.0% |
| 1998 Q2 | 646.03 Thousand EUR | -91.87% |
| 1998 Q3 | 427.27 Thousand EUR | -33.86% |
| 1998 FY | 10.13 Million EUR | 90.05% |
| 1997 FY | 5.33 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 289.373% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 915767.311% |
| SQZ Biotechnologies Company | 9.79 Million USD | 390.014% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 342.645% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 123.847% |
| Mesoblast Limited | -35.16 Million USD | 19.233% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -83074.231% |
| Genus plc | 178.7 Million USD | 115.895% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 7025.018% |
| Marizyme, Inc. | 457.7 Thousand USD | 6305.785% |
| ContraFect Corporation | -154 Thousand USD | -18344.156% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -258118.182% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -56708.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 37103.166% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 43314.46% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -7230.046% |
| MultiCell Technologies, Inc. | 49.32 USD | 57591340.876% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 170.543% |
| EV Biologics, Inc. | 48.9 Thousand USD | 58185.89% |
| Q BioMed Inc. | -8988.00 USD | -315921.362% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 200.527% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -184054.564% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 112.905% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 40677.143% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -22760.178% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 45746.514% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -573486.43% |
| Arch Therapeutics, Inc. | -2439.00 USD | -1164475.646% |
| IMV Inc. | -962.29 Thousand USD | -2851.684% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 20316.37% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -29027.826% |
| GB Sciences, Inc. | -624.00 USD | -4551823.077% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -32917.157% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.376% |
| Halberd Corporation | -208.00 USD | -13655669.231% |
| Enzolytics Inc. | 30.7 Thousand USD | 92597.069% |
| Resverlogix Corp. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 2192.926% |
| SYBLEU INC | 11.69 Thousand USD | 242952.257% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 5987.657% |
| argenx SE | 1.1 Billion USD | 102.562% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | -10.102% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 4700.702% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 106.935% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -320631.707% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 164.034% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -2388.148% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 2974.954% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 395.536% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -33775.18% |
| BioStem Technologies, Inc. | 15.42 Million USD | 284.144% |
| ONE Bio Corp. | 20.12 Million USD | 241.135% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -239900.0% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -58757.415% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 16187.449% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 16187.449% |
| NovAccess Global Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -5420.592% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | -4407.584% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -97844.828% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 6411.397% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -8789.946% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 716.406% |
| Bioxytran, Inc. | -8285.00 USD | -342736.451% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -7515.013% |
| Neutra Corp. | 14.33 Thousand USD | 198244.402% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -34539.024% |
| PureTech Health plc | -1.6 Million USD | -1671.928% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -2736.894% |
| IXICO plc | 3.27 Million USD | 968.624% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -3992.795% |
| Gelesis Holdings, Inc. | -1.79 Million USD | -1485.93% |
| CSL Limited | 7.7 Billion USD | 100.369% |
| Cellectis S.A. | 18 Thousand USD | 157900.0% |